{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-23-000033","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2023-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.796404+00:00","generated_at":"2026-06-13T16:10:19.087400+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"iBio appoints Martin Brenner as permanent CEO and Felipe Duran as permanent CFO","bullets":["Martin Brenner, formerly interim CEO and CSO, appointed permanent CEO; Felipe Duran, formerly interim CFO, appointed permanent CFO, effective June 22, 2023.","Brenner's base salary set at $507,150, including prior $7,500/month interim stipend; granted 75,833 RSUs vesting over 7 months.","Duran's compensation unchanged: base salary of $350,000 with 40% target bonus and $140,000 special incentive bonus.","Board expresses confidence in duo to lead iBio's AI-powered antibody discovery platform and next stage of growth.","Brenner has leadership experience at major pharma including Pfizer and Merck; Duran previously VP of FP&A at iBio."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-23-000033","json":"https://secwatch.observer/filing/0001420720-23-000033.json","markdown":"https://secwatch.observer/filing/0001420720-23-000033.md","text":"https://secwatch.observer/filing/0001420720-23-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000033/0001420720-23-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000033/ibio-20230622x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T16:10:19.087400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56c9f8a9fd","claim":"Martin Brenner was appointed as Chief Executive Officer at iBio, Inc..","evidence_excerpt":"appointed Dr. Martin Brenner its then Interim Chief Executive Officer (CEO), to the position of permanent CEO effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000033/0001420720-23-000033-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}